10-Q: RenovoRx Reports Strong Revenue Growth Amidst Nasdaq Listing Concerns

RenovoRx announces record quarterly revenue and commercial expansion, but faces ongoing challenges with Nasdaq listing compliance and continued net losses.

Summary

• RenovoRx reported record quarterly revenue of $909,000 for Q2 2026, a 115% increase year-over-year, and $1.47 million for the first half of 2026, a 138% increase year-over-year.
• The company expanded its active commercial cancer centers to 21, a 30% increase in the quarter, and maintains a commercial funnel of 63 centers.
• Research and development expenses decreased by 16% year-over-year for the quarter, while selling, general, and administrative expenses increased by 92% due to investments in commercialization.
• The company reported a net loss of $2.91 million for Q2 2026 and $6.43 million for the first half of 2026.
• RenovoRx has cash and cash equivalents of $9.48 million as of June 30, 2026, which is expected to fund operations through at least the next 12 months.
• The company is not currently in compliance with Nasdaq's minimum bid price requirement and has until December 28, 2026, to regain compliance.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with significant revenue growth and commercial expansion offset by continued net losses and Nasdaq listing concerns.

Positives

• Record quarterly revenue of $909,000 in Q2 2026, up 115% from Q2 2025.
• First half 2026 revenue reached $1.47 million, up 138% from the same period in 2025.
• Expansion of active commercial cancer centers to 21, a 30% increase in Q2 2026.
• Total commercial funnel increased to 63 centers.
• Positive interim data from the Phase III TIGeR-PaC study showed a 6-month median overall survival benefit and a significant reduction in adverse events.
• Orphan Drug Designation granted for oxaliplatin for pancreatic cancer treatment.
• Successful completion of a $10 million private placement in March 2026.

Negatives

• Continued net losses, with a loss of $2.91 million in Q2 2026 and $6.43 million in the first half of 2026.
• Accumulated deficit of $67.8 million as of June 30, 2026.
• The company is not in compliance with Nasdaq's minimum bid price requirement and faces potential delisting.
• Reliance on future capital raises to fund operations and development.
• The TIGeR-PaC trial completion is expected in the first half of 2027, with top-line data in the second half of 2027, which is a lengthy timeline.
• Significant increase in Selling, General, and Administrative (SG&A) expenses by 92% year-over-year for Q2 2026.

Risks

• The company has no drug/device combination products approved for commercial sale and limited experience in commercializing standalone medical devices.
• Incurrence of significant net losses and expectation to continue incurring losses until FDA approval for IAG or sufficient RenovoCath revenue is generated.
• The commercial viability of IAG and other product candidates is subject to successful clinical trials and regulatory approvals.
• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• The company may need to raise additional capital, and there is no assurance that such financing will be available on acceptable terms.
• The TIGeR-PaC study's failure to achieve results conducive to progression or NDA approval would significantly harm the company.
• Product candidates may exhibit undesirable side effects, delaying or precluding development or regulatory approval.
• Potential for delisting from Nasdaq if minimum bid price compliance is not achieved by December 28, 2026.

Future Outlook

The company expects to grow revenue from RenovoCath sales sequentially for the remainder of 2026. Research and development expenses are anticipated to increase in the second half of 2026 due to advancements in IAG clinical development and next-generation RenovoCath device development. Selling, general, and administrative expenses are also expected to increase as commercialization activities progress. The company believes its current cash and cash equivalents are sufficient to fund operations through at least the next 12 months, but may require additional capital in the future.

Management Comments

• The combination of record quarterly revenue, rapid active cancer center expansion, and strong repeat ordering behavior demonstrates accelerating commercial momentum and supports the long-term opportunity for RenovoCath as both a standalone device and a foundational platform for future drug-device combination therapies.
• We continue to estimate that the initial total addressable market (TAM) for RenovoCath as a stand-alone device could translate into an approximately $400 million peak annual U.S. sales opportunity for our company. Over time, as we expand the platform into additional solid tumor indications, we believe we could unlock more than $1 billion in peak annual sales potential.
• The completion of enrollment in TIGeR-PaC is a significant milestone for our company which reflects successful patient recruitment, clinical execution, and collaboration among investigators and study teams evaluating IAG as a novel drug-device product candidate for difficult-to-treat LAPC.
• We continue to view the TIGeR-PaC trial as an important long-term value driver, while emphasizing that our commercial strategy and revenue outlook are not dependent on the trial's ultimate outcome or timing.
• We believe that increases in the number publications reporting the use of the TAMP procedure by physicians is another sign of adoption as TAMP traverses from an experimental procedure to becoming a standard of care.

Industry Context

StockSavvy.ai notes that RenovoRx's focus on targeted oncology therapies and its RenovoCath device aligns with the broader industry trend towards personalized medicine and localized drug delivery to improve efficacy and reduce systemic toxicity. The company's strategy to commercialize RenovoCath as a standalone device while simultaneously advancing its IAG drug-device combination product candidate reflects a dual-pronged approach common in the life sciences sector to leverage existing cleared technology while pursuing novel therapeutic development.

Comparison to Industry Standards

• The revenue growth of 115% year-over-year for Q2 2026 and 138% for H1 2026 is strong, particularly for a company in the early commercialization phase of a medical device.
• The expansion of active commercial cancer centers by over 30% in a single quarter is a significant achievement, indicating successful market penetration and adoption.
• The net loss of $2.91 million in Q2 2026, while substantial, is a common characteristic of life sciences companies investing heavily in R&D and commercialization, as seen with companies like Moderna or BioNTech in their earlier stages.
• The company's cash runway of at least 12 months with $9.48 million in cash is a critical metric. While sufficient for the near term, it highlights the ongoing need for future financing, a standard challenge for companies in this sector.
• The TIGeR-PaC trial's interim analysis showing a 6-month median overall survival benefit and reduced adverse events is promising, though the full trial completion and data release are still over a year away, a typical timeline for Phase III oncology trials.

Legal Proceedings

• The company is not currently a party to any material legal proceedings, nor are any material legal proceedings pending or threatened.

Related Party Transactions

• Dr. Ramtin Agah, Chief Medical Officer and Co-Founder, has a consulting agreement for clinical trial oversight.
• Dr. Agah was awarded options to purchase common stock in January 2024 and April/July 2025.
• Consulting fees paid to Dr. Agah for the year ended December 31, 2025, were $337,000.
• Discretionary bonuses were approved for Dr. Agah in March 2026 and December 2025.
• Dr. Agah was appointed Executive Chairman effective February 27, 2026, and entered into an amended consulting agreement.

Stakeholder Impact

• Shareholders may experience dilution if additional equity financing is pursued.
• Potential for increased share price volatility due to Nasdaq listing concerns.
• Patients may benefit from improved cancer treatment options through RenovoCath and IAG.
• Creditors and suppliers will be impacted by the company's ongoing need for capital and its ability to meet financial obligations.

Next Steps

• Continue to expand active commercial cancer centers and drive revenue growth for RenovoCath.
• Advance clinical development of IAG and the next-generation RenovoCath device.
• File a 510(k) with the FDA for the next-generation RenovoCath device.
• Regain compliance with Nasdaq's minimum bid price requirement by December 28, 2026.
• Complete enrollment in the TIGeR-PaC trial and await top-line data in the second half of 2027.

Key Dates

Recommendation

RenovoRx shows promising revenue growth and commercial traction, but the continued net losses, significant cash burn, and the critical Nasdaq listing compliance issue warrant a cautious approach. The long timeline for IAG's clinical trial results also introduces uncertainty. A 'hold' recommendation reflects the balance between positive commercial developments and significant financial and regulatory risks.

Keywords

RenovoCath, TAMP platform, Oncology therapies, Pancreatic cancer, Drug-device combination, Clinical trials, Revenue growth, Commercialization